AD cerebral spinal fluid (CSF) and PET amyloid tracers can be used in the differential diagnosis of FTD from AD, as FTD will likely be negative for these (Meeter et al., 2017), however FTD-specific CSF biomarkers or tau tracers are not available. The gene discussed is MAPT; the disease is Alzheimer disease.